BR0014981A - Derivados de naftiridina - Google Patents
Derivados de naftiridinaInfo
- Publication number
- BR0014981A BR0014981A BR0014981-0A BR0014981A BR0014981A BR 0014981 A BR0014981 A BR 0014981A BR 0014981 A BR0014981 A BR 0014981A BR 0014981 A BR0014981 A BR 0014981A
- Authority
- BR
- Brazil
- Prior art keywords
- derivatives
- naphthyridine derivatives
- salts
- naphthyridine
- substituent
- Prior art date
Links
- 150000005054 naphthyridines Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- ZFRUGZMCGCYBRC-UHFFFAOYSA-N 1h-1,8-naphthyridin-2-one Chemical class C1=CC=NC2=NC(O)=CC=C21 ZFRUGZMCGCYBRC-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"DERIVADOS DE NAFTIRIDINA". Derivados de 2-oxo-1,2-diidro-1,8-naftiridina caracterizados por conter um substituinte específico, -X-R6 na posição-3 e um substituinte cíclico, R5, na posição-4; ou seus sais. Os derivados e os sais são úteis como drogas, particularmente agentes de prevenção ou terapêuticos para doenças respiratórias relacionadas a PDE IV.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP30254499 | 1999-10-25 | ||
PCT/JP2000/007433 WO2001030779A1 (fr) | 1999-10-25 | 2000-10-24 | Derives de naphthyridine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0014981A true BR0014981A (pt) | 2002-07-16 |
Family
ID=17910254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0014981-0A BR0014981A (pt) | 1999-10-25 | 2000-10-24 | Derivados de naftiridina |
Country Status (16)
Country | Link |
---|---|
US (1) | US6740662B1 (pt) |
EP (1) | EP1225173B1 (pt) |
KR (1) | KR100699395B1 (pt) |
CN (1) | CN1148369C (pt) |
AR (1) | AR029185A1 (pt) |
AT (1) | ATE305470T1 (pt) |
AU (1) | AU779081B2 (pt) |
BR (1) | BR0014981A (pt) |
CA (1) | CA2385178A1 (pt) |
DE (1) | DE60022893T2 (pt) |
ES (1) | ES2250200T3 (pt) |
MX (1) | MXPA02004122A (pt) |
PL (1) | PL354600A1 (pt) |
RU (1) | RU2240322C2 (pt) |
TW (1) | TWI262919B (pt) |
WO (1) | WO2001030779A1 (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003076405A1 (en) * | 2002-03-14 | 2003-09-18 | Bayer Healthcare Ag | Monocyclic aroylpyridinones as antiinflammatory agents |
BRPI0412876A (pt) * | 2003-07-22 | 2006-10-03 | Janssen Pharmaceutica Nv | derivados de quinolinona como inibidores de c-fms quinase |
CA2544322C (en) * | 2003-11-20 | 2012-05-08 | Astellas Pharma Inc. | Agent for treating chronic pelvic pain syndrome |
TW200726767A (en) * | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
WO2007097317A1 (ja) * | 2006-02-21 | 2007-08-30 | Eisai R & D Management Co., Ltd. | 4-(3-ベンゾイルアミノフェニル)-6,7-ジメトキシ-2-メチルアミノキナゾリン誘導体 |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
JP5440934B2 (ja) | 2006-05-24 | 2014-03-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換プテリジン |
EP2068872A1 (en) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2008071964A1 (en) * | 2006-12-15 | 2008-06-19 | Astrazeneca Ab | Naphthyridine bactericides |
WO2008099887A1 (ja) * | 2007-02-16 | 2008-08-21 | Eisai R & D Management Co., Ltd. | メチル n-[3-(6,7-ジメトキシ-2-メチルアミノキナゾリン-4-イル)フェニル]テレフタラミックアシッドの結晶、非晶質体または塩 |
JP5060561B2 (ja) | 2007-08-17 | 2012-10-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 新規外用剤 |
EP2189450B1 (en) * | 2007-08-17 | 2011-12-21 | Eisai R&D Management Co., Ltd. | Method for producing quinazoline derivative |
US8426673B2 (en) | 2008-01-11 | 2013-04-23 | Astellas Pharma, Inc. | Pathological animal model for pelvic pain syndrome |
US8815891B2 (en) * | 2008-11-11 | 2014-08-26 | Je Il Pharmaceutical Co., Ltd. | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
WO2013078216A1 (en) * | 2011-11-21 | 2013-05-30 | Advanced Liquid Logic Inc | Glucose-6-phosphate dehydrogenase assays |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
AU2018340475B2 (en) * | 2017-09-28 | 2023-01-19 | Transthera Sciences (Nanjing), Inc. | PDE9 inhibitor and use thereof |
CN111471059B (zh) * | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
US20220160696A1 (en) * | 2019-03-08 | 2022-05-26 | Transthera Sciences (Nanjing), Inc. | Uses of phosphodiesterase inhibitors |
CA3133717C (en) * | 2019-03-15 | 2023-12-05 | Transthera Sciences (Nanjing), Inc. | Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
JPS55164682A (en) * | 1979-06-11 | 1980-12-22 | Yamanouchi Pharmaceut Co Ltd | 1-alkyl-2-oxo-2h-1,8-naphthyridine derivative and its preparation |
EP0267691A3 (en) * | 1986-10-15 | 1989-08-23 | Schering Corporation | Use of 1-substituted naphthyridine and pyridopyrazine derivatives for the preparation of medicaments with immunosuppressor activity. |
US5658924A (en) * | 1992-12-01 | 1997-08-19 | The Green Cross Corporation | 1,8-naphthyridin-2-one derivative and use thereof |
JPH0710875A (ja) * | 1993-06-21 | 1995-01-13 | Green Cross Corp:The | 選択的ホスホジエステラーゼiv阻害剤 |
JPH07126268A (ja) * | 1993-10-29 | 1995-05-16 | Otsuka Pharmaceut Factory Inc | 1,8−ナフチリジン誘導体 |
NZ291507A (en) | 1994-08-29 | 1997-12-19 | Yamanouchi Pharma Co Ltd | 1,8-naphthyridine derivatives; medicaments |
KR100399798B1 (ko) | 1995-05-31 | 2004-05-31 | 스미또모 세이야꾸 가부시키가이샤 | 신규나프티리딘유도체 |
CN1245500A (zh) | 1996-11-26 | 2000-02-23 | 住友制药株式会社 | 新型萘啶衍生物 |
EP1086948A4 (en) | 1998-02-25 | 2004-03-10 | Sumitomo Pharma | PYRIDONE DERIVATIVES AND THEIR MANUFACTURING PROCESS |
-
2000
- 2000-10-23 AR ARP000105559A patent/AR029185A1/es active IP Right Grant
- 2000-10-23 TW TW089122260A patent/TWI262919B/zh not_active IP Right Cessation
- 2000-10-24 PL PL00354600A patent/PL354600A1/xx not_active IP Right Cessation
- 2000-10-24 EP EP00970038A patent/EP1225173B1/en not_active Expired - Lifetime
- 2000-10-24 DE DE60022893T patent/DE60022893T2/de not_active Expired - Lifetime
- 2000-10-24 RU RU2002111005/04A patent/RU2240322C2/ru not_active IP Right Cessation
- 2000-10-24 CA CA002385178A patent/CA2385178A1/en not_active Abandoned
- 2000-10-24 AT AT00970038T patent/ATE305470T1/de not_active IP Right Cessation
- 2000-10-24 BR BR0014981-0A patent/BR0014981A/pt not_active Application Discontinuation
- 2000-10-24 MX MXPA02004122A patent/MXPA02004122A/es active IP Right Grant
- 2000-10-24 AU AU79560/00A patent/AU779081B2/en not_active Ceased
- 2000-10-24 ES ES00970038T patent/ES2250200T3/es not_active Expired - Lifetime
- 2000-10-24 KR KR1020027005261A patent/KR100699395B1/ko not_active IP Right Cessation
- 2000-10-24 CN CNB008147663A patent/CN1148369C/zh not_active Expired - Fee Related
- 2000-10-24 WO PCT/JP2000/007433 patent/WO2001030779A1/ja active IP Right Grant
- 2000-10-24 US US10/111,077 patent/US6740662B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1225173A1 (en) | 2002-07-24 |
MXPA02004122A (es) | 2003-02-12 |
EP1225173A4 (en) | 2003-08-20 |
DE60022893T2 (de) | 2006-07-13 |
AR029185A1 (es) | 2003-06-18 |
WO2001030779A1 (fr) | 2001-05-03 |
CA2385178A1 (en) | 2001-05-03 |
ES2250200T3 (es) | 2006-04-16 |
KR100699395B1 (ko) | 2007-03-27 |
ATE305470T1 (de) | 2005-10-15 |
TWI262919B (en) | 2006-10-01 |
AU779081B2 (en) | 2005-01-06 |
US6740662B1 (en) | 2004-05-25 |
EP1225173B1 (en) | 2005-09-28 |
CN1148369C (zh) | 2004-05-05 |
KR20020041477A (ko) | 2002-06-01 |
DE60022893D1 (de) | 2006-02-09 |
CN1382141A (zh) | 2002-11-27 |
AU7956000A (en) | 2001-05-08 |
RU2240322C2 (ru) | 2004-11-20 |
PL354600A1 (en) | 2004-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0014981A (pt) | Derivados de naftiridina | |
BRPI0417663A (pt) | pirido[2,3-d]pirimidina-2,4diaminas como inibidores de pde 2 | |
PT1244434E (pt) | Utilizacao de agentes quimioterapeuticos | |
MXPA06000231A (es) | Derivados espiro '1-azabiciclo'2.2.2!octan-3,5'-oxazolidin-2'-ona! con afinidad a la alfa7 del receptor nicotinico para acetilcolina. | |
CA2548654A1 (en) | Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | |
AR055669A1 (es) | Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales. | |
BRPI0714320A2 (pt) | Derivado de imidazo[1,2-a] piridina-2-carboxamidas, sua preparação e sua aplicação em terapêutica | |
BR9914040A (pt) | Derivados de [1,2,4]triazolo[1,5-c]pirimidina e seu uso, medicamento, antagonista, agente para prevenir ou tratar doenças, bem como processo para prevenção ou tratamento de distúrbios | |
NO972910L (no) | Tetracykliske spiroforbindelser, fremgangsmåte for fremstilling og anvendelse derav som 5HT1D reseptor-antagonister | |
EP0885894A4 (en) | PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES AND THEIR MEDICAL COMPOUNDS | |
CY1109366T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης | |
YU21701A (sh) | Farmaceutska sredstva za lečenje parkinsonove bolesti, poremećaja nekontrolisane hiperaktivnosti (adhd) i mikroadenoma | |
BRPI0507757A (pt) | composto, composição farmacêutica, e agente terapêutico para uma doença na qual a angiogênese ou a hipermeabilidade vascular está envolvida | |
BRPI0414780B8 (pt) | composto, uso do mesmo, composição farmacêutica, e, método para preparar um composto | |
FR2673627B1 (fr) | Triazines et pyrimidines trisubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant. | |
BR0014826A (pt) | Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm | |
BR0113697A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou sal, embalagem e métodos para, para alterar a atividade transdutora de sinal dos receptores de gabaa, para tratar ansiedade, depressão, um distúrbio do sono, ou demência de alzheimer, para demonstrar a presença dos receptores de gabaa em células ou amostras de tecido e para preparar um composto | |
DE69322251T2 (de) | Medizinische zusammensetzung | |
BRPI0411246A (pt) | composto, uso do mesmo, composição farmacêutica, e, métodos para terapia contra dor em um animal de sangue quente e para a preparação de um composto | |
ES2220975T3 (es) | Tratamiento de trastornos producidos por factores de crecimiento de citoquina. | |
BRPI0415826A (pt) | derivados de ceto-oxadiazol como inibidores de catepsina | |
EA202190036A1 (ru) | Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение | |
SE0002476D0 (sv) | New compounds | |
BRPI0411226A (pt) | composto, uso de um composto, composição farmacêutica, e, método para a terapia contra dor em um animal de sangue quente, e para a preparação de um composto | |
AR054888A1 (es) | Derivados de quinolina como agentes antibacterianos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: ASTELLAS PHARMA INC. (JP) Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8,11,13 E 25 DA LPI |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |